Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

Core Insights - The NAVIGATE trial is focused on patients with MASH cirrhosis and portal hypertension, utilizing non-invasive tests and clinical criteria based on the latest treatment guidelines [1][2] - A significant finding from the trial indicates that approximately one-third of patients screened have detectable esophageal varices, emphasizing the necessity for screening in this population [2][4] - The trial's readout is anticipated in December 2024, with clinical data being presented at the AASLD annual meeting [1][2] Company Overview - Galectin Therapeutics is dedicated to developing therapies for chronic liver disease and cancer, with its lead drug belapectin targeting galectin-3 protein involved in various diseases [5][6] - The company is focusing on metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis, which represents a significant medical need and drug development opportunity [5] - Galectin is also exploring additional development programs in combination immunotherapy for advanced cancers, contingent on finding suitable partnerships [5][6]